News – Page 987 – Endpoints News

Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price

7 years ago

Sage appears set for a breakthrough FDA OK on postpartum depression drug, but who’s going to use it?

7 years ago

Tripped up by the FDA, Novartis says it is dropping out of the US race to win an OK for a blockbuster Rituxan rival

7 years ago

Pfizer racks up its third cancer drug OK in 2 months, but is it enough to replace regular price hikes?

7 years ago

Trevena hammered again as the FDA spurns their controversial pain drug — but AcelRx gets a green light

7 years ago

Kyowa Hakko Kirin gears up to test IDO/PD-1 combo; AbbVie fights Humira biosimilars with 80% price cut in Europe

7 years ago

Omeicos scores $19.5M in Series C to take its omega-3 drug to the next round

7 years ago

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

7 years ago

Experts question Amarin's early touting of Vascepa data ahead of detailed results

7 years ago

Sun BioPharma founder Michael Cullen steps up; SemaThera settles on permanent CEO; OncoSec nabs Kellie Malloy Foerter ...

7 years ago

Tuning in: Intensity's immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

7 years ago

Illumina forks out $1.2B to buy rival Pacific Biosciences, placing long and short-read DNA tech under the same roof

7 years ago

FDA experts gun down Alkermes’ pitch for ALKS-5461, slamming the company on multiple fronts

7 years ago

Urovant's overactive bladder drug scores in mid-stage trial

7 years ago

Vertex wins third CF approval in Europe; ERS Genomics grants DefiniGEN access to CRISPR/Cas9 tech

7 years ago

FDA preps for a new and flexible approach to genome editing in animals

7 years ago

Climbing the blockbuster mountain, Roche/AbbVie team heralds a win in frontline CLL PhIII

7 years ago

GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500

7 years ago

As rivals press in, Stanford spinout Forty Seven burnishes its prospects from an impressive PhIb

7 years ago

6 months after arriving at Sanofi R&D, John Reed gambles $125M on Denali’s RIPK1 work

7 years ago

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect ...

7 years ago

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

7 years ago

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a ...

7 years ago

Gilead throws its weight — and $50M cash — behind Tango's I/O discovery engine

7 years ago

First page Previous page 984 985 986987988 989 990 Next page Last page